Cigna Investments Inc. New Sells 72 Shares of Zoetis Inc. (NYSE:ZTS)

Cigna Investments Inc. New trimmed its position in Zoetis Inc. (NYSE:ZTS) by 1.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,707 shares of the company’s stock after selling 72 shares during the period. Cigna Investments Inc. New’s holdings in Zoetis were worth $920,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of ZTS. Quarry LP grew its stake in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after buying an additional 153 shares in the last quarter. Fortitude Family Office LLC grew its position in shares of Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after purchasing an additional 222 shares during the last quarter. LRI Investments LLC bought a new position in Zoetis during the 1st quarter worth $43,000. Central Valley Advisors LLC acquired a new position in shares of Zoetis in the second quarter valued at about $49,000. Finally, Future Financial Wealth Managment LLC bought a new position in Zoetis during the third quarter worth about $59,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the topic of a number of recent analyst reports. Stifel Nicolaus raised their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Piper Sandler upped their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. upped their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, BTIG Research boosted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Stock Performance

NYSE ZTS opened at $178.78 on Friday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company has a market cap of $81.00 billion, a P/E ratio of 34.99, a PEG ratio of 2.84 and a beta of 0.89. The company has a fifty day simple moving average of $188.95 and a 200 day simple moving average of $178.28. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same quarter in the prior year, the company posted $1.41 earnings per share. Zoetis’s revenue was up 8.3% compared to the same quarter last year. Sell-side analysts predict that Zoetis Inc. will post 5.83 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.97%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 33.86%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.